Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci
Open Access
- 1 July 1995
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 39 (7) , 1522-1525
- https://doi.org/10.1128/aac.39.7.1522
Abstract
The bactericidal effects of Q-35, sparfloxacin, tosufloxacin, and ofloxacin on 18 strains of methicillin-resistant Staphylococcus aureus (MRSA) and 3 strains of Staphylococcus epidermidis were studied by a viable-count method. Staphylococci as used in this study were clearly divided into two groups with respect to their susceptibilities to sparfloxacin. MICs of Q-35 and tosufloxacin were 0.05 to 0.78 microgram/ml for sparfloxacin-susceptible strains (MICs, 0.05 to 0.2 microgram/ml) and 1.56 to 12.5 micrograms/ml for sparfloxacin-resistant strains (6.25 to 25 micrograms/ml). All the sparfloxacin-resistant strains of MRSA tested contained the gyrA mutation at codon 84. Time-kill studies showed that Q-35 decreased the viable counts from approximately 10(7) CFU/ml to 10(3) to 10(5) CFU/ml within 3 h at concentrations greater than the MICs against both sparfloxacin-susceptible and -resistant strains. In contrast, sparfloxacin, tosufloxacin, and ofloxacin produced bacteriostatic effects at 3 h after exposure against sparfloxacin-resistant strains at concentrations which were greater than the respective MICs, whereas these quinolones were bactericidal against sparfloxacin-susceptible strains. The rapid bactericidal activities of Q-35 against sparfloxacin-resistant MRSA were reduced when the methoxy group of Q-35 at the 8 position was substituted with fluorine or hydrogen. Thus, our data suggest that the introduction of a methoxy group into the 8 position of quinolones contributes to the bactericidal activities of fluoroquinolones against quinolone-resistant staphylococci.Keywords
This publication has 14 references indexed in Scilit:
- Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1994
- Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolonesMolecular Microbiology, 1994
- Detection of novel mutations in the gyrA gene of Staphylococcus aureus by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencingAntimicrobial Agents and Chemotherapy, 1994
- Inhibitory Activity on DNA Gyrase and Intracellular Accumulation of Quinolones: Structure-Activity Relationship of Q-35 Analogs.Biological & Pharmaceutical Bulletin, 1994
- Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolonesAntimicrobial Agents and Chemotherapy, 1992
- In vitro antibacterial activity of Q-35, a new fluoroquinoloneAntimicrobial Agents and Chemotherapy, 1992
- Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1991
- Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidisAntimicrobial Agents and Chemotherapy, 1991
- In vitro activity of AT-4140 against clinical bacterial isolatesAntimicrobial Agents and Chemotherapy, 1989
- Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospitalAntimicrobial Agents and Chemotherapy, 1989